INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
(NASDAQ: INMB) Delayed: 1.42 -0.01 (0.7%)
Previous Close $1.43    52 Week High $ 
Open $1.39    52 Week Low $ 
Day High $1.50    P/E N/A 
Day Low $1.39    EPS $ 
Volume 430,480       

(NASDAQ: INMB) Delayed: 1.42 -0.01 (0.7%)
Previous Close $1.43    52 Week High $ 
Open $1.39    52 Week Low $ 
Day High $1.50    P/E N/A 
Day Low $1.39    EPS $ 
Volume 430,480